Zynext Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.10 M
- Company Age 8 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 80.57%
- Profit Growth -6.27%
- Ebitda -372.93%
- Net Worth -4.00%
- Total Assets -20.14%
About Zynext Pharmaceuticals
Zynext Pharmaceuticals Private Limited (ZPPL) is a Private Limited Indian Non-Government Company incorporated in India on 09 November 2016 (Eight years and two months 24 days old ). Its registered office is in Bhopal, Madhya Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Reshu Pathak and Arpan Mishra serve as directors at the Company.
Company Details
-
Location
Bhopal, Madhya Pradesh, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U74999MP2016PTC041816
-
Company No.
041816
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
09 Nov 2016
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Gwalior
Industry
What products or services does Zynext Pharmaceuticals Private Limited offer?
Zynext Pharmaceuticals Private Limited offers a wide range of products and services, including Ayurvedic,Herbal Products & Medicine, Herbal Capsules, Nutraceuticals & Dietary Supplements, Vitamin Tablets & Capsules.
Who are the key members and board of directors at Zynext Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Reshu Pathak
|
Director | 09-Nov-2016 | Current |
|
Arpan Mishra
|
Director | 09-Nov-2016 | Current |
Financial Performance of Zynext Pharmaceuticals.
Zynext Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 80.57% increase. The company also saw a slight decrease in profitability, with a 6.27% decrease in profit. The company's net worth dipped by a decrease of 4%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Zynext Pharmaceuticals?
In 2023, Zynext Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Zynext Pharmaceuticals?
Unlock and access historical data on people associated with Zynext Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Zynext Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Zynext Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.